Expression level of miR-146a correlates with the coronary lesion severity and clinical prognosis in UA patients

Abstract

Abstract Objective To investigate whether there is a connection between the plasma expression level of miR-146a and both the severity of coronary lesion and clinical prognosis in patients with unstable angina pectoris (UA). Methods: 100 unstable angina pectoris(UA group) and 100 healthy controls (Control group) were selected to detect the plasma miRNA-146a expression level. To assess the coronary lesion severity in UA patients by Gensini score, analyze the correlation between miR-146a expression level and the degree of coronary artery stenosis in UA patients. The incidence of major cardiovascular adverse events (MACE) were followed up for 48 months after hospitalization and discharge in UA patients. Using the median grouping method to divide the miR-146a expression level in 100 UA patients into high and low expression groups, analyzing the incidence of MACE in patients with different miRNA-146a expression level by the Kaplan-Meier method. Results: The plasma expression level of miR-146a in the UA group was 1.8 times higher than in the control group (Z=6.970, P <0.001), and was correlated with the severity of coronary lesion; the high expression level was associated with a higher Gensini score (P<0.05). Patients with high miR-146a expression level had a significantly higher incidence of MACE compared to those with low miR-146a expression level (Log-rank: P=0.004). Conclusion: The plasma miR-146a expression level of UA patients was correlated with the severity of coronary lesion, and patients with higher miR-146a expression level had a poor clinical prognosis than those with lower expression level.a pectoris (UA group) and 100 healthy controls (Control group) were selected to detect the plasma miRNA-146a expression level. To assess the coronary lesion severity in UA patients by Gensini score, analyze the correlation between miR-146a expression level and the degree of coronary artery stenosis in UA patients. The incidence of major cardiovascular adverse events (MACE) were followed up for 48 months after hospitalization and discharge in UA patients. Using the median grouping